A Phase 1 Study of Combination Therapy With SAR405838 and Pimasertib in Patients With Advanced Cancer

Trial Profile

A Phase 1 Study of Combination Therapy With SAR405838 and Pimasertib in Patients With Advanced Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2016

At a glance

  • Drugs Pimasertib (Primary) ; SAR 405838 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Feb 2015 Planned End Date changed from 1 Oct 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
    • 27 Aug 2014 Planned number of patients changed from 94 to 100 as reported by ClinicalTrials.gov record.
    • 15 May 2014 Planned End Date changed from 1 Jul 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top